1	A pharmacoepidemiological study of myocarditis and pericarditis following mRNA
2	COVID-19 vaccination in Europe
3	Joana Tome, MPH ¹ , Logan T. Cowan, PhD ¹ , Isaac Chun-Hai Fung, PhD ^{1*}
4	¹ Department of Biostatistics, Epidemiology, and Environmental Health Sciences, Jiann-Ping
5	Hsu College of Public Health, Georgia Southern University, Statesboro, Georgia, United States
6	
7	* Author to whom correspondence should be addressed. Isaac Chun-Hai Fung, PhD, Department
8	of Biostatistics, Epidemiology and Environmental Health Sciences, Jiann-Ping Hsu College of
9	Public Health, Georgia Southern University, PO Box 7989, Statesboro, GA 30460, USA. Tel: +1
10	912-478-5079, Fax: +1 912-478-0171, <u>cfung@georgiasouthern.edu</u> , ORCID 0000-0001-5496-
11	2529
12	
13	Disclaimer: The views expressed in the submitted manuscript are ours and not an official
14	position of any institution or funder.
15	Source(s) of support: None
16	Word Count (excluding abstract, captions, references): 3,339
17	Number of tables: 4
18	
19	
20	
21	
22	
23	
24	

25 ABSTRACT

26	Purpose: To assess myocarditis and pericarditis reporting rate as adverse drug reactions (ADRs)
27	for the messenger ribonucleic acid (mRNA) coronavirus disease 2019 (COVID-19) vaccines
28	authorized in Europe.
29	Methods: Data on myocarditis and pericarditis related to mRNA COVID-19 vaccines (period:

30 January 1, 2021 - February 11, 2022) were collected from the EudraVigilance database and

31 combined with the European Centre for Disease Prevention and Control's (ECDC) vaccination

32 tracker database. The reporting rate was expressed as 1 million individual vaccinated-days with a

33 corresponding 95% confidence interval (CI), and an observed-to-expected (OE) analysis was

34 performed to check if there was an excess risk for myocarditis or pericarditis following mRNA

35 COVID-19 vaccination.

36 **Results:** The reporting rate of myocarditis per 1 million individual vaccinated-days in the study

37 period was 17.27 (95% CI, 16.34-18.26) for the CX-024414 vaccine and 8.44 (95% CI, 8.18-

8.70) for TOZINAMERAN vaccine. The reporting rate for pericarditis per 1 million individual

39 vaccinated-days in the study period was 9.76 (95% CI, 9.06-10.51) for the CX-024414 vaccine

40 and 5.79 (95% CI, 5.56-6.01) for TOZINAMERAN vaccine. The OE analysis showed that both

41 vaccines produced a myocarditis standardized morbidity ratio (SMR) greater than 1, with the

42 CX-024414 vaccine having a greater SMR than TOZINAMERAN. Regarding

43 TOZINAMERAN, SMR for pericarditis was greater than 1 when considering the lowest

44 background incidence, but smaller than 1 when considering the highest background incidence.

45 **Conclusions:** Our results suggest an excess risk of myocarditis following the first dose of

46 mRNA COVID-19 vaccine, but the relationship between pericarditis and mRNA COVID-19

47 vaccine remains unclear.

48 **KEYWORDS**

49 COVID-19; adverse drug reaction; myocarditis; pericarditis; COVID-19 mRNA vaccine.

50 ABBREVIATIONS

- 51 ADRs adverse drug reactions
- 52 CI confidence interval
- 53 COVID-19 coronavirus disease 2019
- 54 ECDC European Centre for Disease Prevention and Control
- 55 EEA European Economic Area
- 56 EMA European Medicines Agency
- 57 EU European Union
- 58 mRNA messenger ribonucleic acid
- 59 OE observed-to-expected
- 60 OR odds ratio
- 61 PRAC Pharmacovigilance Risk Assessment Committee
- 62 RNA ribonucleic acid
- 63 SARS-CoV-2 severe acute respiratory syndrome coronavirus 2
- 64 SMR standardized morbidity ratio
- 65
- 66
- 67
- 68
- 69
- ____
- 70

71 **INTRODUCTION**

72 Myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the heart's outer lining) following immunizations such as smallpox, influenza, hepatitis B, or other 73 vaccines have previously been reported as a rare side effect.¹⁻³ Depending on the source, the 74 incidence of myocarditis and pericarditis in the European Economic Area (EEA) has ranged 75 from 1 to 10 in 100,000 people per year.⁴ European Medicines Agency (EMA)'s safety 76 77 committee, the Pharmacovigilance Risk Assessment Committee (PRAC), started reviewing cases of myocarditis and pericarditis following Pfizer-BioNTech (TOZINAMERAN) and Moderna 78 (CX-024414) COVID-19 vaccination since April 2021. Increased rates of cases of myocarditis 79 and pericarditis following mRNA COVID-19 vaccination were also noticed in the United States⁵ 80 and Canada.⁶ 81

82 TOZINAMERAN and CX-024414, the two mRNA vaccines being used in the European Union (EU)/EEA, contain an mRNA molecule with instructions for producing the spike protein 83 from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that stimulates the body's 84 immune response.⁴ There are different biological mechanisms that can explain the possible 85 86 association between mRNA COVID-19 vaccination and the occurrence of myocarditis and pericarditis. Based on preliminary evidence from adult trials with mRNA vaccinations, it is rare 87 but possible that antibody responses to mRNA vaccines can become very high, causing cardiac 88 inflammation.⁷ One other mechanism is the activation of anti-idiotype cross-reactive antibody-89 mediated cytokine expression in the myocardium, as well as abnormal apoptosis, which can 90 result in myocardial and pericardial inflammation.⁸ The mRNA vaccines may possibly trigger a 91 non-specific innate inflammatory response or a molecular mimicry mechanism between the viral 92

93	spike protein and an unknown cardiac protein. ⁹ The last explanation is that vaccinations' potent
94	immunogenic RNA can have a bystander or adjuvant consequence on the heart. ¹⁰
95	Although the occurrence of myocarditis and pericarditis following SARS-CoV-2
96	infection seems to be more frequent and serious, ¹¹⁻¹³ assessing the risk of myocarditis and
97	pericarditis after COVID-19 mRNA immunization has its own importance.
98	Previous studies indicate that the incidence of myocarditis and pericarditis may increase
99	following COVID-19 mRNA immunization; ¹⁴⁻¹⁸ therefore, it is critical to determine the
100	magnitude of the association between myocarditis or pericarditis occurrence and mRNA
101	COVID-19 vaccination in order to protect the most vulnerable population and to aid in the
102	differentiation of the COVID-19 vaccination's risks and benefits. Moreover, many clinical trials
103	were unable to identify rare adverse events of COVID-19 vaccines because they were
104	underpowered. Their detection is critical for risk-benefit analyses and informing post-vaccination
105	clinical practice. Therefore, detecting such adverse events through pharmacovigilance post-
106	authorization has become a global scientific priority.
107	To enhance risk communication that accompanies existing COVID-19 vaccination
108	campaigns, this study aims to quantify the elevated risk, if any, of myocarditis and pericarditis 28
109	days following Tozinameran and CX-024414 vaccination among Europeans using publicly
110	available data from the EU/EEA in an exploratory way. This study used an OE analysis, which is
111	a part of the quantitative pharmacovigilance toolkit for vaccines, to calculate the standardized
112	morbidity ratio (SMR).
113	MATERIAL AND METHODS

We hypothesize that myocarditis and pericarditis SMRs greater than 1 will result from
both the mRNA COVID-19 vaccines. A combination of two databases was used in this

pharmacoepidemiological study. The participants were European people from the EU/EEA countries who were eligible for the mRNA COVID-19 vaccines that were available in Europe during the 2021-2022 periods. All the variables included in this analysis are named/defined as classified in their respective databases.

ECDC has a vaccination tracker database¹⁹ that gathers reports from the EU/EEA 120 countries. These countries submit data to the ECDC through The European Surveillance System 121 122 (TESSy) twice a week (Tuesdays and Fridays). The database contains aggregated data on the number of vaccine doses distributed by manufacturers to the EU/EEA countries, the number of 123 124 first, second, additional, and unspecified doses administered to different age groups and in 125 specific target groups, such as healthcare workers and in residents in long-term care facilities. The database includes data on the COVID-19 vaccination rollout, where each row contains the 126 127 corresponding data for a certain week and country. The database is publicly available and was downloaded on February 16, 2022. From this database, we extracted the number of individuals 128 129 from the EU/EEA countries who received their first dose of CX-024414 and TOZINAMERAN 130 vaccines that also represents our exposure variable. Technically, being vaccinated with the first dose of the CX-024414 or TOZINAMERAN vaccines (including a time window from the date 131 132 when the mRNA COVID-19 vaccines became eligible for vaccination in Europe till February 16, 2022) is considered as our exposure variable. In the analysis, it was used as the sum of the 133 individuals from the EU/EEA countries who received their first dose of CX-024414 and 134 135 TOZINAMERAN vaccines during the time window period, which also represents our study 136 population size.

EudraVigilance²⁰ is a public available pharmacovigilance database of suspected ADR
reports. Data was downloaded from EudraVigilance on February 16, 2022. The database

139	contains cardiac problems related to COVID-19 vaccination using mRNA vaccines (CX-024414
140	and TOZINAMERAN) reported from January 1, 2021, to February 11, 2022. Among all cardiac
140	and TOZH (MULICHT) reported from January 1, 2021, to Teordary 11, 2022. Among an eardiae
141	problems, our outcomes of interest are myocarditis and pericarditis. The database contains the
142	EU local number (identification number), type of report, the date when the report was received,
143	the source of the report, age group, sex, the vaccine type, the adverse event, the duration,
144	outcome, and seriousness of the adverse event, the duration, dose, and the route of administration
145	of the vaccine, the type of concomitant, and the duration, dose, and the route of administration of
146	any concomitant received by the patient. In this analysis, we used the number of myocarditis and
147	pericarditis ADRs, the age group, sex, and the vaccine as the other needed variables. The ADR
148	outcomes were treated as the sum of the number of myocarditis or pericarditis reported in the
149	study period. Age group categories were classified as 5-11, 12-17, 18-64, 65-85 years old, more
150	than 85 years old, and not specified. Sex was classified as female, male, and not specified. The
151	vaccine variable was represented by the CX-024414 and TOZINAMERAN vaccines. No missing
152	data were observed from both the databases.
153	Myocarditis and pericarditis reporting rates during the study period (January 1, 2021, to
154	February 11, 2022) were estimated using the formulae: ²¹
155	-for myocarditis: the number of myocarditis ADRs reported in the study period the number of individuals who received their first dose of vaccine in the study period
156	-for pericarditis: the number of pericarditis ADRs reported in the study period the number of individuals who received their first dose of vaccine in the study period.
157	The OE analysis was performed within 28 days post the first vaccine dose, considering
158	the estimated lowest and highest myocarditis and pericarditis background incidence rates
159	reported by the EMA. ⁴ The background incidence rate represents the number of new cases
160	naturally occurring in the EEA, expressed as person-time, and was estimated for the EEA
161	population before it was exposed to any of the mRNA COVID-19 vaccines. The person-time at

risk was calculated as the number of first doses \times (28/365.2425) \times (1/100,000).²¹ The OE ratio 162 was expressed as an SMR with a 95% CL.²¹ The analysis was performed using the 'epiR' 163 package in R version 4.0.3 (R Core Team, R Foundation for Statistical Computing, Vienna, 164 165 Austria). Patient and public involvement 166 Only publicly available data are used in this study. This study was determined by Georgia 167 168 Southern University's Institution Review Board (IRB) (H20364) to be exempt from full review under the G8 exemption category (Non-human subjects determination): This project does not 169 170 involve obtaining information about living individuals or does not have direct interaction or 171 intervention with individuals or their personal data so is not defined as human subjects research 172 under human subjects regulations. As well, no patient or public was involved in the study design 173 or the data collection, analysis, or interpretation procedures. 174 RESULTS In the study period, there were 73,466,253 people in the EU who received the first dose 175 of the CX-024414 vaccine and 484,402,251 who received their first dose of the 176 177 TOZINAMERAN vaccine. In the same period, there were 9,078 and 38,297 individuals in 178 EU/EEA countries reported with adverse cardiac problems after the administration of the CX-179 024414 vaccine and the TOZINAMERAN vaccine, respectively. Of these reports, there were 1,269 and 4,087 myocarditis events reported for CX-024414, and for TOZINAMERAN 180 181 respectively (Table 1), and 717 and 2,803 pericarditis events for CX-024414 and 182 TOZINAMERAN, respectively (Table 2). The reporting rate of myocarditis per 1 million 183 individual vaccinated-days in the study period was 17.27 (95% CI, 16.34-18.26) for the CX-184 024414 vaccine and 8.44 (95% CI, 8.18-8.70) for TOZINAMERAN vaccine. The reporting rate

- 185 for pericarditis per 1 million individual vaccinated-days in the study period was 9.76 (95% CI,
- 186 9.06-10.51) for the CX-024414 vaccine and 5.79 (95% CI, 5.56-6.01) for TOZINAMERAN
- 187 vaccine.
- 188 **Table 1.** All myocarditis ADRs stratified by age group and sex.

Vaccine name,	Patient	F	Patient Sex		Myocarditis
n of total cardiac ADRs	Age Group				ADRs
(Jan 1, 2021-Feb 11,		Female	Male	NS	n (%)
2022)					
Moderna (CX-024414)	12-17 Years	5	67	0	72 (5.67)
N=9,078	18-64 Years	231	883	6	1,120 (88.26)
	65-85 Years	29	27	0	56 (4.41)
	More than 85	2	1	0	3 (0.24)
	Not Specified	6	10	2	18 (1.42)
	Total (%)	273	988	8	1,269 (100)
		(21.51)	(77.86)	(0.63)	
Pfizer-BioNTech	5-11 Years	3	4	0	7 (0.17)
(TOZINAMERAN)	12-17 Years	65	492	5	562 (13.75)
N=38,297	18-64 Years	897	2,187	22	3,106 (76.00)
	65-85 Years	122	122	2	246 (6.02)
	More than 85	11	12	0	23 (0.56)

Vaccine name,	Patient	ŀ	atient Sex		Myocarditis
n of total cardiac ADRs	Age Group				ADRs
(Jan 1, 2021-Feb 11,		Female	Male	NS	n (%)
2022)					
	Not Specified	40	85	18	143 (3.50)
	Total (%)	1,138	2,902	47	4,087 (100)
		(27.84)	(71.01)	(1.15)	

Abbreviations: ADRs, adverse drug reactions; n, number; NS, not specified.

189

190 **Table 2.** All pericarditis ADRs stratified by age group and sex.

Vaccine name, <i>n</i> of total cardiac ADRs	Patient Age Group	Patient Sex			Pericarditis ADRs
(Jan 1, 2021-Feb 11, 2022)		Female	Male	NS	n (%)
Moderna (CX-024414)	12-17 Years	5	7	0	12 (1.67)
N=9,078	18-64 Years	266	336	4	606 (84.52)
	65-85 Years	46	43	0	89 (12.41)
	More than 85	2	0	0	2 (0.28)
	Not Specified	4	4	0	8 (1.12)
	Total (%)	323	390	4	717

Vaccine name,	Patient	Patient Sex			Pericarditis
n of total cardiac ADRs	Age Group				ADRs
(Jan 1, 2021-Feb 11,		Female	Male	NS	n (%)
2022)					
		(45.05)	(54.39)	(0.56)	
Pfizer-BioNTech	12-17 Years	49	89	0	138 (4.92)
(TOZINAMERAN)	18-64 Years	1,157	1,068	10	2,235 (79.74)
N=38,297	65-85 Years	160	184	0	344 (12.27)
	More than 85	15	25	0	40 (1.43)
	Not Specified	24	20	2	46 (1.64)
	Total (%)	1,405	1,386	12	2,803
		(50.12)	(49.45)	(0.43)	

Abbreviations: ADRs, adverse drug reactions; n, number; NS, not specified.

191
192**Tables 3** and **4** presented the OE analyses for both vaccines using two background193incidence rates, namely 1 and 10 per 100,000 persons per year, respectively. For myocarditis, the194results showed an SMR >1 for both vaccines, with the CX-024414 vaccine having a greater195SMR than that of TOZINAMERAN. For pericarditis, both vaccines had an SMR >1 when196considering the lowest background incidence; however, when the highest background incidence197was considered, the SMR for TOZINAMERAN was <1 while that for CX-024414 was >1. Still,

- regarding pericarditis, the CX-024414 vaccine had greater SMRs than those of the
- 199 TOZINAMERAN vaccine.
- 200 **Table 3.** Observed-to-expected analysis for myocarditis.

Vaccine	Person-time	Background	Expected	Observed	SMR
name	at risk	incidence	Myocarditis	Myocarditis	(95% <mark>C</mark> I)
	(100,000	(lowest,			
	person-years)	highest)			
Moderna	56.32	1	56.32	1,269	22.53
(CX-024414)					(21.31-23.81)
		10	563.2		2.253
					(2.13-2.38)
Pfizer-	371.35	1	371.35	4,087	11.01
BioNTech					(10.67-11.35)
(TOZINAME		10	3,713.5		1.10
RAN)					(1.07-1.14)

Abbreviations: SMR, standardized morbidity ratio; CI, confidence interval.

201

202 **Table 4.** Observed-to-expected analysis for pericarditis.

Vaccine	Person-time	Background	Expected	Observ<mark>ed</mark>	SMR
name	at risk	incidence	Pericarditis	Pericarditis	(95% CI)
	(100,000	(lowest,			
	person-years)	highest)			
Moderna	56.32	1	56.32	717	12.73

(CX-024414)					(11.82-13.70)
		10	563.2		1.27
					(1.18-1.37)
Pfizer-	371.35	1	371.35	2,803	7.55
BioNTech					(7.27-7.83)
(TOZINAME		10	3,713.5		0.75
RAN)					(0.73-0.78)

Abbreviations: SMR, standardized morbidity ratio; CI, confidence interval.

203

204 DISCUSSION

In this study, we used data from EudraVigilance to evaluate the occurrence of 205 206 myocarditis and pericarditis after mRNA COVID-19 vaccination. The majority of myocarditis and pericarditis' ADRs were reported among 18-64 years old people. Myocarditis occurred 207 mostly among male cases, while for pericarditis, there were slightly more ADRs among males 208 209 for CX-024414 and slightly more ADRs among females for the TONZINAMERAN vaccine. However, these results should be interpreted cautiously because data on the vaccination rate 210 211 stratified by age and sex are absent in this study. The reporting rate of myocarditis and 212 pericarditis per 1 million individual vaccinated-days in the study period was greater for CX-213 024414 compared to TOZINAMERAN. The SMR for myocarditis was greater than 1 for both 214 vaccines (showing excess risk), with the CX-024414 vaccine having a greater SMR than 215 TOZINAMERAN. For pericarditis, the results showed an SMR > 1 when considering the lowest 216 background incidence; however, when the highest background incidence was considered, the 217 TOZINAMERAN vaccine showed a smaller than 1 SMR. In either case, the pericarditis SMRs for CX-024414 were greater than that for TOZINAMERAN. 218

219	In Germany, surveillance data from the Paul Ehrlich Institute reported a rate for
220	myocarditis in men 18-29 years old of 11.71 cases per 100,000 COVID-19 Moderna vaccine
221	recipients in German data and 7.79 in the Moderna Global Safety Database. ²² Furthermore, two
222	other large European studies reported the occurrence of myocarditis and pericarditis after
223	COVID-19 mRNA vaccination. ²² The first one, the Nordic cohort study of 23 million residents
224	of Denmark, Finland, Norway, and Sweden, observed that during the 28-day risk periods
225	following vaccination, 1,092 incident myocarditis cases and 1,154 incident pericarditis cases
226	occurred. Among them, 106 and 123 myocarditis cases occurred following first- and second-dose
227	vaccinations with TOZINAMERAN, respectively, and 15 and 67 following CX-024414,
228	respectively. The second one, the population-based case-control study in France, ²² showed a
229	large increase in the myocarditis odds within seven days after vaccination. In this study, the
230	association with the risk of myocarditis appeared particularly pronounced in young men under 30
231	years of age, particularly after the second dose of the CX-024414 vaccine (odds ratio (OR) 79.8;
232	95% CI [29.8-213.4]). A Danish population-based cohort study observed that vaccination with
233	the Moderna vaccine was significantly associated with an increased risk of myocarditis among
234	12-39 years old people, while vaccination with the Pfizer-BioNTech vaccine was significantly
235	associated with an increased risk among women. ²³

Meanwhile, it is noteworthy to mention that the risk of myocarditis among adolescents was found in one study to be lower after a booster compared to the second dose of the Pfizer-BioNTech COVID-19 vaccine.²⁴

While an elevated risk of myocarditis following vaccination with mRNA COVID-19 vaccine was observed, the evidence regarding pericarditis remained equivocal. The populationbased case-control study in France observed an increased risk of pericarditis in people under 30

years of age, in particular after the second dose in men (OR 15.0, 95% CI [3.3-68.4]) and after
the first dose in women (OR 27.9, 95% CI [2.4-328.0]), ²² while the Danish population-based
cohort study observed an increased risk of pericarditis among 12-39 years old people. ²³ On the
other hand, Patone et al.²⁵ observed that there was no evidence of an increased risk of pericarditis
following vaccination, except in 1 to 28 days after the second dose of the Moderna vaccine.
Furthermore, Diaz et al.¹⁸ reported that pericarditis affected older patients later, after either the
first or second dose.

The elevated risk of myocarditis (and perhaps pericarditis) after receiving mRNA 249 COVID-19 vaccine should be evaluated in light of the greater risk of myocarditis or pericarditis 250 following SARS-CoV-2 infection.²⁵ Oberweis et al.²⁶ suggested that cardiac injury from SARS-251 CoV-2 can be caused directly (e.g., through angiotensin-converting enzyme 2 binding in the 252 253 heart) and indirectly through a toxic inflammatory reaction with cytokine storm, with the indirect 254 mechanism being more frequent. Furthermore, the authors hypothesized that some children have 255 died from COVID-19 because they may have been more susceptible to heart damage from the 256 cytokine storm caused by COVID-19 than the standard respiratory distress syndrome seen in adults. 257

Even though the rare occurrence of myocarditis and pericarditis can be deadly, the majority of myocarditis cases linked to vaccines have been mild and self-limiting,¹⁷ whereas SARS-CoV-2 infection may carry a serious risk of morbidity and mortality over time, especially for the unvaccinated. Myocardial injury was highly common among hospitalized COVID-19 patients.²⁷ Patone et al.²⁵ emphasized that compared to the risk from COVID-19 vaccine, SARS-CoV-2 infection was associated to a significant increase in the risk of myocarditis, pericarditis, and cardiac arrhythmia-related hospitalization or death. Therefore, the benefits of SARS-CoV-2

265 mRNA vaccination that lowers both the risk of infection and the risk of hospitalization should be 266 considered when interpreting the results of our study.

Furthermore, our results should be interpreted in light of the fact that myocarditis and pericarditis have also occurred following immunizations such as smallpox, influenza, hepatitis B, or other vaccines.¹⁻³

Our study is subject to certain limitations. First, we cannot directly compare the reporting 270 271 rate of myocarditis or pericarditis to the incidence rate in the general EU/EEA population 272 because they represent different measures that use different definitions of the time at risk. 273 Consequently, whether the incidence of myocarditis or pericarditis is higher in vaccinated people than in the general population is beyond the scope of this study. Since we do not know the exact 274 background incidence rate, which may vary substantially among different vaccine group 275 populations, as well as knowing that the data were based on different assumptions,²⁸ the findings 276 277 should be interpreted with caution. Second, we cannot exclude the possibility of ADRs' 278 registration underestimation. There is a possibility of underreporting myocarditis and 279 pericarditis, which can impose non-differential misclassification. Third, we were unable to 280 calculate myocarditis and pericarditis incidence for each vaccine that is adjusted for demographics and other factors because the information on confounding is absent; except for sex 281 282 and age group, information on other variables was missing. Fourth, the reporting rates were not standardized for age due to the unavailability of the data; therefore, we were unable to perform a 283 stratified OE analysis. A vaccine's safety profile may vary depending on the target population 284 285 (e.g., higher risks in the youngest age groups); therefore, comparing reporting rates for age groups or countries should be avoided because it would introduce biases and inaccuracies. 286 287 CONCLUSION

- 288 To conclude, our study analysis supports an excess risk of myocarditis following the first
- dose of the mRNA COVID-19 vaccine, but the direction of the relationship between pericarditis
- and mRNA COVID-19 vaccine remains unclear. Future research is needed to calculate age and
- sex standardized reporting rates, stratified OE analyses, as well as analyses following the second
- or more doses of mRNA COVID-19 vaccine. The benefits of COVID19 vaccination exceed the
- risks of adverse events; however, pharmacovigilance methods continue to play a pivotal role in
- 294 monitoring, identifying, and reducing ADR risk.
- 295 ACKNOWLEDGEMENTS
- 296 None.
- 297 CONFLICT OF INTERESTS
- None declared.
- 299 FUNDING
- 300 This research did not receive any specific grant from funding agencies in the public, commercial,
- 301 or not-for-profit sectors.

302 CONTRIBUTORSHIP

- 303 Joana Tome Research question generation, literature review, data analysis and interpretation,
- 304 manuscript preparation.
- 305 Logan T. Cowan Manuscript preparation and review.
- 306 Isaac Chun-Hai Fung Literature review, manuscript preparation, and review.
- 307 All authors attest they meet the ICMJE criteria for authorship.
- 308
- 309
- 310

311 **REFERENCES**

- 312 [1] Su JR, McNeil MM, Welsh KJ, et al. Myopericarditis after vaccination, Vaccine Adverse Event
- 313 Reporting System (VAERS), 1990–2018. *Vaccine*. 2021/01/29/ 2021;39(5):839-845.
- 314 **[2]**Bozkurt B, Kamat I, Hotez PJ. Myocarditis With COVID-19 mRNA Vaccines. *Circulation*.
- 315 2021;144(6):471-484.
- 316 **[3]** Mei R, Raschi E, Forcesi E, Diemberger I, De Ponti F, Poluzzi E. Myocarditis and pericarditis after
- immunization: Gaining insights through the Vaccine Adverse Event Reporting System. *Int J Cardiol.* Dec
 15 2018;273:183-186.
- 319 [4] EMA. COVID-19 vaccines: update on ongoing evaluation of myocarditis and pericarditis. Available
- at: <u>https://www.ema.europa.eu/en/news/covid-19-vaccines-update-ongoing-evaluation-myocarditis-</u>
 pericarditis. Accessed 4/27/2022.
- 322 **[5]** CDC. Advisory Committee on Immunization Practices (ACIP) june 2021 presentation slides.
- 323 Coronavirus disease 2019 (COVID-19) vaccines. . Available at:
- 324 <u>https://www.cdc.gov/vaccines/acip/meetings/slides-2021-06.html</u> Accessed 4/27/2022.
- 325 **[6]** PHAC. Statement from the Council of Chief Medical Officers of Health (CCMOH): update on COVID-19
- 326 vaccines and the risk of myocarditis and pericarditis. Ottawa, ON: Government of Canada. Available at:
- 327 <u>https://www.canada.ca/en/public-health/news/2021/10/statement-from-the-council-of-chief-medical-</u>
- 328 officers-of-health-ccmoh-update-on-covid-19-vaccines-and-the-risk-of-myocarditis-and-
- 329 pericarditis.html. Accessed 4/27/2022.
- 330 [7] Grimaud M, Starck J, Levy M, et al. Acute myocarditis and multisystem inflammatory emerging
- disease following SARS-CoV-2 infection in critically ill children. *Annals of intensive care.* 2020;10(1):6969.
- 333 **[8]** Das BB, Moskowitz WB, Taylor MB, Palmer A. Myocarditis and Pericarditis Following mRNA COVID-19
- 334 Vaccination: What Do We Know So Far? *Children (Basel)*. Jul 18 2021;8(7).
- 335 [9] Segal Y, Shoenfeld Y. Vaccine-induced autoimmunity: the role of molecular mimicry and immune
- 336 crossreaction. *Cell Mol Immunol.* Jun 2018;15(6):586-594.
- 337 **[10]** Root-Bernstein R, Fairweather D. Unresolved issues in theories of autoimmune disease using
- 338 myocarditis as a framework. *J Theor Biol.* Jun 21 2015;375:101-123.
- [11] Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in
 Wuhan, China. *Lancet.* Feb 15 2020;395(10223):497-506.
- 341 **[12]** Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel
- 342 Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020;323(11):1061-1069.
- 343 **[13]** Guo T, Fan Y, Chen M, et al. Cardiovascular Implications of Fatal Outcomes of Patients With
- 344 Coronavirus Disease 2019 (COVID-19). *JAMA Cardiology*. 2020;5(7):811-818.
- 345 [14] Klein NP, Lewis N, Goddard K, et al. Surveillance for Adverse Events After COVID-19 mRNA
- 346 Vaccination. *JAMA*. 2021;326(14):1390-1399.
- 347 **[15]** Shimabukuro T. Covid-19 vaccine safety updates cdc.gov. *Centers for Disease Control and*
- 348 *Prevention.* June 23, 2021 2021:50.
- 349 **[16]** Barda N, Dagan N, Ben-Shlomo Y, et al. Safety of the BNT162b2 mRNA Covid-19 Vaccine in a
- 350 Nationwide Setting. *N Engl J Med.* Sep 16 2021;385(12):1078-1090.
- 351 **[17]** Witberg G, Barda N, Hoss S, et al. Myocarditis after Covid-19 Vaccination in a Large Health Care
- 352 Organization. *New England Journal of Medicine*. 2021;385(23):2132-2139.
- **[18]** Diaz GA, Parsons GT, Gering SK, Meier AR, Hutchinson IV, Robicsek A. Myocarditis and Pericarditis
- 354 After Vaccination for COVID-19. *JAMA*. 2021;326(12):1210-1212.
- 355 [dataset] [19] ECDC. Data on COVID-19 vaccination in the EU/EEA. 4/21/2022. Available at:
- 356 <u>https://www.ecdc.europa.eu/en/publications-data/data-covid-19-vaccination-eu-eea</u>. Accessed 2/16/2022.

- 357 [dataset] [20] EudraVigilance. European Database of suspected adverse drug reaction. European
- 358 *Medicines Agency*. Available at: <u>https://www.adrreports.eu/</u>. Accessed 2/16/2022.
- 359 [21] Abbattista M, Martinelli I, Peyvandi F. Comparison of adverse drug reactions among four COVID-19
- 360 vaccines in Europe using the EudraVigilance database: Thrombosis at unusual sites. *Journal of*
- 361 thrombosis and haemostasis : JTH. 2021;19(10):2554-2558.
- 362 [22] EMAPRAC. Signal assessment report on myocarditis and pericarditis with Spikevax COVID-19
- 363 mRNA vaccine (nucleosidemodified). *European Medicines Agency*. 2021:47.
- [23] Husby A, Hansen JV, Fosbøl E, et al. SARS-CoV-2 vaccination and myocarditis or myopericarditis:
 population based cohort study. *BMJ*. 2021;375:e068665.
- 366 [24] Kuehn BM. Myocarditis Adverse Event Less Common After COVID-19 Vaccine Booster. JAMA.
- 367 2022;327(14):1324-1324.
- 368 [25] Patone M, Mei XW, Handunnetthi L, et al. Risks of myocarditis, pericarditis, and cardiac arrhythmias
- associated with COVID-19 vaccination or SARS-CoV-2 infection. *Nature Medicine*. 2022/02/01
 2022;28(2):410-422.
- 371 **[26]** Oberweis M-L, Codreanu A, Boehm W, et al. Pediatric Life-Threatening Coronavirus Disease 2019
- 372 With Myocarditis. *The Pediatric Infectious Disease Journal*. 2020;39(7).
- 373 [27] Sandoval Y, Januzzi JL, Jr., Jaffe AS. Cardiac Troponin for Assessment of Myocardial Injury in COVID-
- 19: JACC Review Topic of the Week. *J Am Coll Cardiol.* Sep 8 2020;76(10):1244-1258.
- 375 [28] Mahaux O, Bauchau V, Van Holle L. Pharmacoepidemiological considerations in observed-to-
- 376 expected analyses for vaccines. *Pharmacoepidemiology and drug safety*. 2016;25(2):215-222.